Cargando…

Exploring new treatment options for polycystic ovary syndrome: Review of a novel antidiabetic agent SGLT2 inhibitor

Polycystic ovary syndrome (PCOS) is the most common endocrinopathy in women of reproductive age associated with long-term metabolic and cardiovascular consequences. A plethora of symptoms and their severity differentiate on an individual level, giving the syndrome numerous phenotypes. Due to menstru...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marinkovic-Radosevic, Jelena, Cigrovski Berkovic, Maja, Kruezi, Egon, Bilic-Curcic, Ines, Mrzljak, Anna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2021
Materias:	Opinion Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8311482/ https://www.ncbi.nlm.nih.gov/pubmed/34326946 http://dx.doi.org/10.4239/wjd.v12.i7.932

Ejemplares similares

What is the gut feeling telling us about physical activity in colorectal carcinogenesis?
por: Berkovic, Maja Cigrovski, et al.
Publicado: (2020)

How far along are we in revealing the connection between metformin and colorectal cancer?
por: Berkovic, Maja Cigrovski, et al.
Publicado: (2021)

Semaglutide might be a key for breaking the vicious cycle of metabolically associated fatty liver disease spectrum?
por: Cigrovski Berkovic, Maja, et al.
Publicado: (2022)

NAFLD and Physical Exercise: Ready, Steady, Go!
por: Cigrovski Berkovic, Maja, et al.
Publicado: (2021)

Prehabilitation of overweight and obese patients with dysglycemia awaiting bariatric surgery: Predicting the success of obesity treatment
por: Cigrovski Berkovic, Maja, et al.
Publicado: (2022)

Post-transplant diabetes mellitus and preexisting liver disease - a bidirectional relationship affecting treatment and management
por: Cigrovski Berkovic, Maja, et al.
Publicado: (2020)

Shifting perspectives – interplay between non-alcoholic fatty liver disease and insulin resistance in lean individuals
por: Bilic-Curcic, Ines, et al.
Publicado: (2021)

Fear of hypoglycemia, a game changer during physical activity in type 1 diabetes mellitus patients
por: Cigrovski Berkovic, Maja, et al.
Publicado: (2021)

Coagulation and Endothelial Dysfunction Associated with NAFLD: Current Status and Therapeutic Implications
por: Ogresta, Doris, et al.
Publicado: (2022)

The Effects of Transition from Bedtime to Morning Glargine Administration in Patients with Poorly Regulated Type 1 Diabetes Mellitus: Croatian Pilot Study
por: Gradiser, Marina, et al.
Publicado: (2015)

Malignant insulinoma: Can we predict the long-term outcomes?
por: Cigrovski Berkovic, Maja, et al.
Publicado: (2022)

Glucagon-like-1 receptor agonists and sodium/glucose cotransporter-2 inhibitors combination—are we exploiting their full potential in a real life setting?
por: Cigrovski Berkovic, Maja, et al.
Publicado: (2020)

Are We Compensating for the Lack of Physical Activity in Our Diabetic Patients with Treatment Intensification?
por: Cigrovski Berkovic, Maja, et al.
Publicado: (2017)

Long-Term Effectiveness of Liraglutide in Association with Patients’ Baseline Characteristics in Real-Life Setting in Croatia: An Observational, Retrospective, Multicenter Study
por: Berkovic, Maja Cigrovski, et al.
Publicado: (2017)

Effect of COVID-19 on management of type 1 diabetes: Pushing the boundaries of telemedical healthcare
por: Bilic Curcic, Ines, et al.
Publicado: (2021)

Psoriasis Severity—A Risk Factor of Insulin Resistance Independent of Metabolic Syndrome
por: Polic, Melita Vuksic, et al.
Publicado: (2018)

The effectiveness of lixisenatide as an add on therapy to basal insulin in diabetic type 2 patients previously treated with different insulin regimes: a multi-center observational study
por: Božek, Tomislav, et al.
Publicado: (2018)

Flash Glucose Monitoring in Croatia: The Optimal Number of Scans per Day to Achieve Good Glycemic Control in Type 1 Diabetes
por: Canecki-Varzic, Silvija, et al.
Publicado: (2023)

The prognostic role of diabetes mellitus type 2 in the setting of hepatocellular carcinoma: a systematic review and meta-analysis
por: Mrzljak, Anna, et al.
Publicado: (2022)

Prognostic role of metformin in diabetes mellitus type 2 patients with hepatocellular carcinoma: A systematic review and meta-analysis
por: Cigrovski Berkovic, Maja, et al.
Publicado: (2023)

Obesity Paradox in Chronic Liver Diseases: Product of Bias or a Real Thing?
por: Curcic, Ines Bilic, et al.
Publicado: (2019)

Polycystic Ovary Syndrome: Challenges and Possible Solutions
por: Che, Yue, et al.
Publicado: (2023)

Assessment of FreeStyle Libre Flash Glucose Monitoring System Implementation in Real Life Clinical Setting: A Prospective Observational Study
por: Canecki Varzic, Silvija, et al.
Publicado: (2021)

Novel Antidiabetic Medications in Polycystic Ovary Syndrome
por: Somagutta, Manoj Reddy, et al.
Publicado: (2022)

Management of Glycemia during Acute Aerobic and Resistance Training in Patients with Diabetes Type 1: A Croatian Pilot Study
por: Ivandic, Marul, et al.
Publicado: (2023)

SGLT inhibitors as antidiabetic agents: a comprehensive review
por: Kshirsagar, Rahul P., et al.
Publicado: (2020)

Association of Asymmetric Dimethylarginine and Nitric Oxide with Cardiovascular Risk in Patients with End-Stage Liver Disease
por: Dragičević, Maro, et al.
Publicado: (2020)

Treatment options for polycystic ovary syndrome
por: Badawy, Ahmed, et al.
Publicado: (2011)

The Potential of SGLT-2 Inhibitors in the Treatment of Polycystic Ovary Syndrome: The Current Status and Future Perspectives
por: Rakic, Dejana, et al.
Publicado: (2023)

Semaglutide-eye-catching results
por: Cigrovski Berkovic, Maja, et al.
Publicado: (2023)

Immunomodulatory Effects of SGLT2 Inhibitors—Targeting Inflammation and Oxidative Stress in Aging
por: Schönberger, Ema, et al.
Publicado: (2023)

Polycystic ovary syndrome (PCOS) and COVID-19: an overlooked female patient population at potentially higher risk during the COVID-19 pandemic
por: Kyrou, Ioannis, et al.
Publicado: (2020)

Fertility Treatment Options for Women With Polycystic Ovary Syndrome
por: Sawant, Shital, et al.
Publicado: (2019)

An update of polycystic ovary syndrome: causes and therapeutics options
por: Rababa’h, Abeer M., et al.
Publicado: (2022)

Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes
por: Ninčević, Vjera, et al.
Publicado: (2019)

Impact of SGLT-2 Inhibition on Cardiometabolic Abnormalities in a Rat Model of Polycystic Ovary Syndrome
por: Pruett, Jacob E., et al.
Publicado: (2021)

Computed tomography colonography and radiation risk: How low can we go?
por: Popic, Jelena, et al.
Publicado: (2021)

Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents
por: Vivian, Eva M
Publicado: (2014)

Molecular Modeling Studies of Thiophenyl C-Aryl Glucoside SGLT2 Inhibitors as Potential Antidiabetic Agents
por: Sharma, Mukesh C., et al.
Publicado: (2014)

Hepatitis E virus in professionally exposed: A reason for concern?
por: Mrzljak, Anna, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6ko5vjf7325fljhlbeu15osb4n